Zio ECG Utilization Software (ZEUS) System vs Tempus ECG-AF

Tool A offers a dedicated web portal (ZioSuite) and a mobile application for healthcare professionals, along with a patient-facing app, providing a direct and comprehensive user experience for managing continuous ECG data. In contrast, Tool B explicitly states it does not have a dedicated user interface, relying solely on integration with existing healthcare facility systems, which may limit direct user interaction and specialized workflow management.

Tool A provides a comprehensive solution for the diagnosis and ongoing management of cardiac arrhythmias through continuous, long-term monitoring (up to 14 days) and detailed end-of-wear reports with a 99% physician agreement rate. Tool B focuses specifically on risk prediction for new-onset AF in a defined population, which is valuable for early identification but has a narrower scope and is not intended for patient monitoring or as a sole basis for diagnosis or treatment.

Tool B clearly outlines CMS reimbursement availability with specific CPT codes and a Medicare rate, providing transparency and a clear financial pathway for adoption by healthcare providers. Tool A's pricing information is not publicly available, making it difficult to assess its value proposition without direct vendor contact.

Both tools demonstrate strong enterprise readiness. Tool A offers a robust cloud-based platform with HL7 EHR integration and dedicated portals for clinicians and patients, along with international regulatory clearances (CE Mark). Tool B also integrates seamlessly into existing healthcare facility systems via standard protocols and is compatible with major ECG hardware vendors, leveraging EHR data for patient filtering and having a major academic medical center as an early adopter.

While both are innovative, Tool A's approach of integrating AI with wearable biosensors for continuous, long-term monitoring and providing a comprehensive end-to-end service for diagnosis and management represents a more disruptive innovation in how cardiac data is collected and utilized outside traditional clinical settings. Tool B's innovation lies in applying AI to existing 12-lead ECGs for risk prediction, which is valuable but less transformative in the data acquisition paradigm.

Tool A provides easily accessible Instructions for Use documents, a dedicated customer care contact (email and phone), and a comprehensive web portal (ZioSuite) that includes user administration and patient support resources. While Tool B offers technical support contacts and a document library, Tool A's publicly available and detailed documentation, combined with multiple support channels and patient resources, suggests a more robust and transparent support ecosystem.